Effects of MK-3475 on the breast tumor microenvironment in triple negative breast cancer with andwithout intra-operative RT: a Window of Opportunity study
A study for patients with triple negative breast cancer using study drug KEYTRUDA before breast surgery (TBNC)
Sponsor: Merck
Enrolling: Female Patients Only
IRB Number: AAAQ7863
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is for women with triple negative breast cancer who have received no prior chemotherapy and are scheduled to undergo breast conserving surgery. We are doing this research study to learn more about how newly diagnosed TNBC responds to Pembrolizumab by giving two cycles of the drug before breast conserving surgery. Pembrolizumab (also known as KEYTRUDA) is an FDA-approved immunotherapy prescription drug used to treat patients with metastatic melanoma, a type of skin cancer. This has not been FDA-approved to treat patients with breast cancer however it is being actively investigated in TNBC. It is also being investigated for the treatment of other cancers. Pembrolizumab (also known as KEYTRUDA) is a medicine that may treat cancer by working with your immune system. The aim of this study is to collect blood, tumor tissue and breast tissue from patients with newly diagnosed TNBC tumors, following two cycles of pembrolizumab and assess the immune response in the primary tumor, surrounding normal breast tissue and serum from these patients.
This study is closed
Eileen Connolly, MD, PhD
Do You Qualify?
Hav you been diagnosed with Triple Negative Breast Cancer (TNBC)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator